Percutaneous revascularization of chronic coronary occlusions: an overview.
暂无分享,去创建一个
R. Califf | R. Harrington | J. Tcheng | R. Stack | M. Sketch | H. Phillips | J A Puma | M H Sketch | J E Tcheng | R A Harrington | H R Phillips | R S Stack | R M Califf | J. Puma | Robert A. Harrington | Robert A Harrington
[1] H. Trappe,et al. Natural history of single vessel disease. Risk of sudden coronary death in relation to coronary anatomy and arrhythmia profile. , 1989, European heart journal.
[2] A. Jacobs,et al. Results of coronary angioplasty of chronic total occlusions (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Angioplasty Registry). , 1992, The American journal of cardiology.
[3] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.
[4] J. Margolis,et al. Diffuse Embolization Following Percutaneous Transluminal Coronary Angioplasty of Occluded Vein Grafts: The Blush Phenomenon , 1991, Clinical cardiology.
[5] L. Hillis,et al. Influence of residual antegrade coronary blood flow on survival after myocardial infarction in patients with multivessel coronary artery disease , 1990 .
[6] G. Vetrovec,et al. Early and late outcome of percutaneous transluminal coronary angioplasty for subacute and chronic total coronary occlusion. , 1986, American heart journal.
[7] A. Colombo,et al. Coronary angioplasty of chronic occlusions: factors predictive of procedural success. , 1992, American heart journal.
[8] Foss Mv. HOMOSEXUAL PRACTICE AND VENEREAL DISEASES. , 1964, Lancet.
[9] D. Kereiakes,et al. Angioplasty in total coronary artery occlusion: experience in 76 consecutive patients. , 1985, Journal of the American College of Cardiology.
[10] L. Hillis,et al. Does restoration of antegrade flow in the infarct‐related coronary artery days to weeks after myocardial infarction improve long‐term survival? , 1992 .
[11] W Rutishauser,et al. Percutaneous transluminal coronary angioplasty for chronic total coronary arterial occlusion. , 1987, The American journal of cardiology.
[12] F H Sheehan,et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.
[13] S. Kelsey,et al. Effect of investigator experience on percutaneous transluminal coronary angioplasty. , 1984, The American journal of cardiology.
[14] P. Golino,et al. Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. , 1989, Journal of the American College of Cardiology.
[15] B. Waller,et al. Anatomy, histology, and pathology of coronary arteries: A review relevant to new interventional and imaging techniques‐part iv , 1992, Clinical cardiology.
[16] Y. Ohtsuki,et al. ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.
[17] H. Rapold. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation , 1990, The Lancet.
[18] J. Maraganore,et al. Anticoagulant activity of synthetic hirudin peptides. , 1989, The Journal of biological chemistry.
[19] W J Penny,et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. , 1989, Circulation.
[20] D. Pryor,et al. The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. , 1994, The New England journal of medicine.
[21] T. Bowker,et al. Percutaneous transluminal coronary angioplasty in chronic coronary artery occlusion. , 1993, Journal of the American College of Cardiology.
[22] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.
[23] J. Simpson,et al. Effect of lesion characteristics on outcome of directional coronary atherectomy. , 1991, Journal of the American College of Cardiology.
[24] B. Meier,et al. Magnum wire for balloon recanalization of chronic total coronary occlusions. , 1989, The American journal of cardiology.
[25] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[26] G. Stone,et al. Procedural outcome of angioplasty for total coronary artery occlusion: an analysis of 971 lesions in 905 patients. , 1990, Journal of the American College of Cardiology.
[27] V. Bufalino,et al. Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts by extended infusion of urokinase: initial results and short-term clinical follow-up. , 1991, Journal of the American College of Cardiology.
[28] C. McCabe,et al. Initial success and long-term follow-up of percutaneous transluminal coronary angioplasty in chronic total occlusions versus conventional stenoses. , 1988, The American journal of cardiology.
[29] M. Leon,et al. Chronic total obstruction and short-term outcome: the Excimer Laser Coronary Angioplasty Registry experience. , 1993, Mayo Clinic proceedings.
[30] E. Topol,et al. Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast , 1993, Circulation.
[31] A. Jaffe,et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. , 1986, Journal of the American College of Cardiology.
[32] P. Serruys,et al. Percutaneous transluminal angioplasty of a totally occluded venous bypass graft: a challenge that should be resisted. , 1989, The American journal of cardiology.
[33] V. Fuster,et al. Role of Thrombin in Arterial Thrombosis: Implications for Therapy , 1991, Thrombosis and Haemostasis.
[34] E. Topol,et al. Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion. , 1989, The American journal of cardiology.
[35] B. Meier. Total coronary occlusion: a different animal? , 1991, Journal of the American College of Cardiology.
[36] W. Weintraub,et al. Percutaneous Transluminal Coronary Angioplasty of Chronic Total Occlusions: Primary Success, Restenosis, and Long‐term Clinical Follow‐up , 1992, Circulation.
[37] H. Hecht,et al. Lesion morphology and coronary angioplasty: current experience and analysis. , 1992, Journal of the American College of Cardiology.
[38] J. Wilcox. Thrombin and other potential mechanisms underlying restenosis. , 1991, Circulation.
[39] G. Roubin. Interventional Cardiovascular Medicine: Principles and Practice , 1994 .
[40] W. Rutishauser,et al. Long-term results of successful and failed angioplasty for chronic total coronary arterial occlusion. , 1990, The American journal of cardiology.
[41] P. Serruys,et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. , 1993, Circulation.
[42] N Sulke,et al. Determinants of success of coronary angioplasty in patients with a chronic total occlusion: a multiple logistic regression model to improve selection of patients. , 1993, British heart journal.
[43] Burton E. Sobel,et al. Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor , 1991, Circulation.
[44] F. Schwarz,et al. Intraoperative evaluation of the functional significance of coronary collateral vessels in patients with coronary artery disease. , 1978, The American journal of cardiology.
[45] P. Siegl,et al. Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide: A Potent Inhibitor of Coagulation Factor Xa in a Primate Model of Arterial Thrombosis , 1991, Circulation.
[46] H. Schaff,et al. Angioplasty in total coronary artery occlusion. , 1984, Journal of the American College of Cardiology.
[47] M. Bell,et al. Balloon angioplasty of chronic total coronary artery occlusions: what does it cost in radiation exposure, time, and materials? , 1992, Catheterization and cardiovascular diagnosis.
[48] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[49] K. Kuck,et al. Recanalization of chronic, totally occluded coronary arteries by new angioplasty systems. , 1990, The American journal of cardiology.
[50] K. Friedman,et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.
[51] R. Jordan,et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. , 1989, Circulation.
[52] S. Kaul,et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. , 1992, The New England journal of medicine.
[53] A. Jacobs,et al. Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty. , 1991, The American journal of cardiology.
[54] D. Hunt,et al. Coronary angioplasty for chronic total occlusion reduces the need for subsequent coronary bypass surgery. , 1990, American heart journal.
[55] R. Califf,et al. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. , 1989, Journal of the American College of Cardiology.
[56] M. Cohen,et al. Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. , 1989, Journal of the American College of Cardiology.
[57] P. Serruys,et al. Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. , 1985 .
[58] J. Maraganore,et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.
[59] K. Bailey,et al. Initial and Long‐term Outcome of 354 Patients After Coronary Balloon Angioplasty of Total Coronary Artery Occlusions , 1992, Circulation.
[60] H. Gold,et al. Kistrin, a Polypeptide Platelet GPIIb/IIIa Receptor Antagonist, Enhances and Sustains Coronary Arterial Thrombolysis With Recombinant Tissue‐Type Plasminogen Activator in a Canine Preparation , 1991, Circulation.
[61] J. Griffin,et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. , 1990, Circulation.
[62] V. Bufalino,et al. Prolonged infusion of urokinase for recanalization of chronically occluded aortocoronary bypass grafts. , 1988, The American journal of cardiology.
[63] E. Braunwald,et al. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.
[64] W. Edwards,et al. Balloon angioplasty of aortocoronary saphenous vein bypass grafts: a histopathologic study of six grafts from five patients, with emphasis on restenosis and embolic complications. , 1988, Journal of the American College of Cardiology.
[65] J O'Keefe,et al. A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .